medRxiv preprint doi: https://doi.org/10.1101/2024.10.29.24316282; this version posted November 4, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license .

1 2	The Basel Long COVID Cohort Study (BALCoS): protocol of a prospective cohort study
3 4	Authors: *Stefan Rohner ^{1,2} , *Rebekka Schnepper ^{2,3} , Gunther Meinlschmidt ^{3,4} , Rainer
4 5	Schaefert ^{1,2} , Michael Mayr ^{1,5} , ♦Katrin Bopp ^{1,5} , ♦Andrea Meienberg ^{1,5}
5 6	* shared first authorship
0 7	 shared last authorship
8	
9	Author Affiliations:
10	¹ University of Basel, Faculty of Medicine, Basel, Switzerland
11	² University Hospital Basel, Department of Psychosomatic Medicine, Basel, Switzerland
12	³ University Hospital Basel, Department of Digital and Blended Psychosomatics and
13	Psychotherapy, Basel, Switzerland
14	⁴ University of Trier, Department of Clinical Psychology and Psychotherapy, Trier, Rheinland-
15	Pfalz, Germany
16	⁵ University Hospital Basel, Medical Outpatient Clinic, Basel, Switzerland
17	
18	Authors' ORCID-IDs:
19	Stefan Rohner: https://orcid.org/0000-0002-4812-6433
20	Rebekka Schnepper: https://orcid.org/0000-0002-5415-5943
21	Gunther Meinlschmidt: https://orcid.org/0000-0002-3488-193X
22	Rainer Schaefert: https://orcid.org/0000-0002-3077-7289
23	Michael Mayr: <u>https://orcid.org/0000-0002-1962-8186</u>
24	Katrin Bopp: <u>https://orcid.org/0000-0001-6398-4375</u>
25	Andrea Meienberg: https://orcid.org/0000-0002-0751-2469
26	Short title: PAL CoS atudy protocol
27 28	Short title: BALCoS study protocol
28 29	Protocol Version: 1.4
30	
31	Sponsors: Prof. Dr. med. Rainer Schaefert, PD Dr. med. Michael Mayr
32	epeneerer i ien. Dit med. Ramer conderert, i D Dit med. Michael Mayr
33	Principle Investigator: Prof. Dr. Gunther Meinlschmidt, gunther.meinlschmidt@unibas.ch
34	
35	Co-Investigators: Dr. rer. nat. Rebekka Schnepper, Dr. med. Andrea Meienberg, Dr. med.
36	Katrin Bopp
37	
38	Corresponding Author: Dr. med. Andrea Meienberg, andrea.meienberg@usb.ch
39	
40	Submitting Author: Stefan Rohner, <u>stefan.rohner@usb.ch</u>
41	
42	Number of figures: 1
43	
44	Number of tables: 3
45	Ward county 1005
46	Word count: 4625

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

perpetuity. It is made available under a CC-BY-NC 4.0 International license .

47 **ABSTRACT**

48 Introduction The recent severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) pandemic had a devasting global impact. Many people suffered from coronavirus disease 49 2019 (COVID-19) and some experienced persistent symptoms interrupting their lives even 50 further. The World Health Organization (WHO) defined the condition of these persistent 51 52 symptoms as post-COVID-19 condition (PCC). The most prevalent PCC symptoms are fatigue, 53 dyspnea, sleep disturbances, coughing, anosmia and ageusia, chest pain, and headaches. This article describes the protocol of the Basel Long COVID Cohort Study (BALCoS), which 54 aims at fostering understanding of PCC and investigating underlying mechanisms for the 55 56 development and course of the condition by focusing on participants' health status and symptoms with repeated measures over one year. 57

Methods and analysis BALCoS is a prospective single site cohort study. Inclusion criteria are 58 a confirmed PCC diagnosis according to WHO or a subjective attribution of persistent 59 symptoms to PCC, proficiency in German to follow study procedures, and at least 18 years of 60 61 age. It comprises blood sample collections, standardized neurocognitive and psychometric 62 tests, physical performance measures, and ecological momentary assessments (EMAs). Standardized tests and EMAs are administered at baseline (BL), and at 3-, 6-, and 12-months 63 64 follow-up. At BL and 12-month follow-up, physical performance and neurocognitive abilities are assessed. Participants provide blood samples at BL. The study is exploratory in nature and a 65 sample size of at least 120 participants is targeted. The study is part of a larger Horizon Europe 66 Long COVID project combining mechanistic, clinical, and intervention studies within an 67 interdisciplinary European research consortium. 68

Ethics and dissemination The Ethics Commission of Northwest and Central Switzerland
 approved the study (BASEC-ID: 2023-00359), which is registered at ClinicalTrial.gov (ID:
 NCT05781893). All participants provide written informed consent. Key results from the study
 will be published in peer-reviewed journals.

73 **Funding Details** BALCoS is primarily funded by the Swiss State Secretariat for Education,

Research and Innovation (SERI) under contract number 22.00094 in the context of the

European Union's Horizon Europe research and innovation program under grant agreement
 No. 101057553.

77

Keywords: cohort study, SPIROS, post-COVID, long COVID, post-acute sequelae of SARS CoV-2, PASC, study protocol

80

81 **Conflict of Interest Statement**

GM received funding from the Stanley Thomas Johnson Stiftung & Gottfried und Julia 82 Bangerter-Rhyner-Stiftung under projects no. PC 28/17 and PC 05/18, from Health Promotion 83 84 Switzerland under project no. 18.191/K50001, from the Swiss Heart Foundation under project 85 no. FF21101, from the Research Foundation of the International Psychoanalytic University (IPU) Berlin under projects no. 5087 and 5217, from the Swiss National Science Foundation 86 (SNSF) under project no. 100014 135328, from the German Federal Ministry of Education and 87 88 Research under budget item 68606, from the Hasler Foundation under project No. 23004, from SERI under contract number 22,00094 in the context of a European Union (Horizon Europe) 89 research consortium "Long COVID" (funding number: 101057553) and from Wings Health in 90 the context of a proof-of-concept study. GM is a co-founder and shareholder of Theravou AG. 91 active in digital and blended mental healthcare. GM receives royalties from publishing 92 93 companies as author, including a book published by Springer, and an honorarium from Lundbeck for speaking at a symposium. Furthermore, GM is compensated for providing 94 psychotherapy to patients, acting as a supervisor, serving as a self-experience facilitator 95 96 ('Selbsterfahrungsleiter'), and for postgraduate training of psychotherapists, psychosomatic 97 specialists, and supervisors.

RaS received funding from Promotion Santé Suisse (Gesundheitsförderung Schweiz) under contract no. 18.191/K50001, from the Health Department Basel-City, from SERI under contract number 22.00094 in the context of a European Union (Horizon Europe) research consortium
 "Long COVID" (funding number: 101057553), and from Wings Health in the context of a proof of concept study. RaS is coeditor of the German AWMF S3-Guidelines on Functional

103 Complaints and contributed to the German guidelines on irritable bowel syndrome, and on Lyme Borreliosis. RaS is chairman of the Basel Institute for Psychosomatic Medicine (BIPM), 104 and founder and managing director of the Psychosomatic and Psychosocial Services GmbH, 105 that develops and implements psychosomatic and psychosocial training and continuing 106 education programs. RaS is member of the Swiss Academy of Psychosomatic and 107 108 Psychosocial Medicine (SAPPM) – where he is member of the Scientific Advisory Board, of 109 the Société Médicale Suisse d'Hypnose (SMSH), of the Dt. Kollegium für Psychosomatische 110 Medizin (DKPM), of the Dt. Gesellschaft für Psychosomatische Medizin und Ärztliche Psychotherapie (DGPM), and of the German Balint Society (DBG). RaS serves as spokesman 111 112 of DKPM and DGPM for Consultation and Liaison Psychosomatics. He is a member of the board of trustees of the Foundation Psychosomatic and Social Medicine (Ascona Foundation). 113 MM served as a consultant for AstraZeneca, Boehringer Ingelheim, Bayer and received 114 unrestricted grants from Menarini, AstraZeneca, Bayer, Bristol-Myers Squibb Pfizer, Daiichi 115 Sankyo, GlaxoSmithKline, IBSA, Lilly, MSD, Novo Nordisk, Sanofi-Aventis, and Viatris. 116

117 ReS received funding from SERI under contract number 22.00094 in the context of a European 118 Union (Horizon Europe) research consortium "Long COVID" (funding number: 101057553).

AM received unrestricted grants from Menarini, AstraZeneca, Bayer, Bristol-Myers Squibb Pfizer, Daiichi Sankyo, GlaxoSmithKline, IBSA, Lilly, MSD, Novo Nordisk, Sanofi-Aventis, and Viatris.

122

126

127

123 Strengths and Limitations

- Repeated assessments are expected to inform about the course of illness
 progression and development within routine medical care.
 - A broad array of participant-reported outcomes strengthens participant perspective of symptoms.
- The duration of data collection and the number of questionnaires might influence questionnaire completion and adherence.
- Planned follow-up of 12 months limits conclusions regarding long-term outcome.
- The exploratory nature of the study allows to explore risk factors and associations,
 but not causality.

medRxiv preprint doi: https://doi.org/10.1101/2024.10.29.24316282; this version posted November 4, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license.

INTRODUCTION 133

134 In early 2020, the coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has led to a global pandemic. As the 135 pandemic progressed, it became apparent that the disease not only causes acute symptoms 136 but can also lead to long-term complaints (sometimes termed "long COVID", in the following 137 referred to as "post-COVID-19 condition", PCC). According to the definition of the World Health 138 139 Organization (WHO), PCC is defined as symptoms occurring in individuals with a history of 140 confirmed or suspected SARS-CoV-2 infection, lasting for at least two months, usually within three months from the onset of the acute infection, that cannot be explained by an alternative 141 142 diagnosis (1). Generally, symptoms are heterogeneous (2) and present across multiple organ systems. Common symptoms include fatigue, dyspnea, sleep disturbances, coughing, 143 anosmia and ageusia, chest pain, headaches (3). According to a meta-analysis conducted in 144 March 2022, the prevalence of PCC ranges from 7.5% to 41% in non-hospitalized adults and 145 averages 37.6% in hospitalized adults (4). Due to methodological differences in the published 146 147 literature, prevalence rates vary considerably and numbers are difficult to reliably estimate.

148 Even though some risk factors of PCC could be identified, such as virus variant, female gender, hypertension, smoking, obesity, and comorbid diseases (5-9), the etiology of PCC is still 149 150 unclear (10, 11). Several hypotheses have been proposed, such as immune dysregulation (12), microbiota dysbiosis which affects the microbiota and virome, including the persistence 151 of SARS-CoV-2 (13), autoimmunity and primed immune cells by molecular mimicry (14), 152 microvascular coagulation with endothelial dysfunction (15), and dysfunctional signaling in the 153 brainstem and/or vagus nerve (16). These findings show that biomedical components have 154 been the focus of PCC research. However, psychological factors are also increasingly 155 considered and have been shown to play an important role (17). These factors are incorporated 156 157 into psychotherapeutic treatment approaches (18). Due to insufficient understanding of the 158 mechanisms that underlie the development of PCC, treatment options are currently limited and mainly focus on symptom management. This lack of understanding potentially contributes to 159 160 those affected by PCC experiencing feelings of helplessness, frustration, being misunderstood, worry due to the uncertain course of the disease, and a sense of losing control 161 over their lives (19). A better understanding of the pathogenesis, risks, and protective factors 162 163 of PCC would help to improve health care and support of people affected with PCC (20, 21). Here we provide the protocol of the Basel Long COVID Cohort study (BALCoS), which aims 164 to investigate and better understand PCC, its symptoms and course, and to illuminate the 165

underlying multifactorial mechanisms of the condition by collecting a broad biopsychosocial 166 spectrum of data over the course of one year. Participants complete a set of assessments that 167 include the collection of sociodemographic and clinical data, biomarkers, neurocognitive 168 testing, psychometric questionnaires, ecological momentary assessments (EMAs), and 169 170 measures of physical performance. This research serves as a basis for planning future 171 measures and provides information on clinically relevant factors for health care professionals. 172 From this research it may be possible to derive factors that positively influence the quality of 173 care of patients and their overall quality of life.

METHODS AND ANALYSIS 175

176

174

Study Design and Setting 177

BALCoS is a registry-based, single-center, prospective, observational cohort study. The study 178 site is located at the Medical Outpatient Clinic of the University Hospital Basel (UHB) and 179 participants are recruited from patients attending the specialized PCC consultation service at 180 181 the UHB. In addition, study participation is open to individuals from consultation services and 182 clinics outside the UHB and individuals who respond to study advertisements. Written consent 183 is required from all participants.

184

185 **Study Timeline**


186 Recruitment started in February 2023, with the first participant enrolled in April 2023. The study

187 is intended to extend beyond the current SERI-funded research period, which runs until May

perpetuity. It is made available under a CC-BY-NC 4.0 International license .

- 188 2026 to allow for further data collection and analysis, as well as continued scrutiny of the
- research questions, including changes in PCC over time (see Figure 1).
- 190

191 Figure 1. Timeline of the Basel Long COVID Cohort Study.



192

193 Note: SERI = State Secretariat for Education, Research, and Innovation; COVID = coronavirus disease.

194

195 Study Schedule

Participants are asked to give informed consent to the inclusion of all their data from previous 196 medical examinations that could be relevant to their PCC symptoms. Further, they are asked 197 to agree that the data collected in the study can be used for routine clinical care. Participants 198 199 not recruited from the UHB PCC clinic provide this information in an enrollment interview, after signing the informed consent form. An overview of all clinical information collected at the 200 201 baseline interview and routine clinical examination can be young in the supplemental material. 202 At baseline (BL) and T3, participants complete psychometric measures and neurocognitive tests on a computer, tablet, or similar device. If the BL assessment is too exhausting for one 203 204 visit, a second visit can be arranged to complete the neurocognitive test battery and measures of physical performance (marked with "(x)" in Table 1). Participants can choose to complete 205 206 the study remotely, if travelling to the study site is not feasible due to health concerns or 207 symptom burden. These participants complete the study as planned, except for the completion 208 of physical performance measures, neurocognitive assessments, and blood sample collection at BL. Remote participants receive a link by email to complete the psychometric measures for 209 210 BL and T3 online at home. At T1 and T2, all participants (remote and in-person) receive a link by email to a battery of psychometric questionnaires to complete online at home. One day after 211 completing each data collection point (BL, T1, T2, and T3), participants receive a link via text 212 message at 6 p.m. directing them to the EMA questions. These 8 EMA questions are answered 213 214 over ten consecutive days. A detailed summary of the study plan is provided in Table 1.

215

216 **Table 1.** Outcome measures and assessment schedule.

	Outcome measure	BL		T1	T2	Т3
		1	2			
0	Oral and written information, written consent, screening of inclusion and exclusion criteria	х				
1	Blood samples*	х				
2	Neurocognitive assessment: Central Nervous System Vital Signs (CNSVS) *	х	(x)			х
3	Physical performance measures*					
а	6-minute walking test	Х	(x)			Х
b	Jamar dynamometer	х	(x)			х
С	1-minute sit-to-stand test (STS-60)	х	(x)			Х
4	Psychometric questionnaires	•				
а	Functional Capacity: World Health Organization Disability Assessment Schedule (WHODAS 2.0)	х		х	х	х

perpetuity. It is made available under a CC-BY-NC 4.0 International license .

b	Visual Analogue Scales (VASs): quality of life, symptom intensity, functional impairment, work ability	x		x	x	х
С	Quality of Life: Quality-of-Life-8 (EuroHIS QOL-8)	х		х	х	х
d	Somatic Symptom Severity: Patient Health Questionnaire (PHQ-15)	x		x	x	х
е	Somatic Distress: Somatic Symptom Disorder – B Criteria Scale (SSD-12)	х		х	х	х
f	Depression : Patient Health Questionnaire Depression Scale (PHQ-8)	х		х	х	х
g	Anxiety: Generalized Anxiety Disorder Questionnaire (GAD-7)	х		х	х	х
h	Resilience: Resilience Scale (RS-11)	х		х	х	Х
i	Insomnia: Insomnia Severity Index (ISI)	Х		Х	Х	Х
j	Fatigue : Chalder Fatigue Scale (CFS)	х		х	х	х
k	Stress: Perceived Stress Scale (PSS-10)	Х		Х	Х	Х
6	Ecological momentary assessments (EMAs; 8 daily questions for 10 consecutive days after BL, T1, T2, T3)		х	х	х	х

217 Note: BL = Baseline

- 218 *Measurements not completed by remote participants
- 219

220 Sampling procedure and selection

- Enrollment is based on the inclusion criteria (see Table 2) and recruitment is carried out by the
- study team which includes physicians, psychologists, psychotherapists, and study nurses.
- 223
- Table 2. Inclusion and exclusion criteria.

Inclusion criteria	Exclusion criteria
Confirmed PCC diagnosis according to WHO or subjective attribution of persistent symptoms to PCC	Lack of general understanding of the study procedures
At least 18 years of age	Rejection of consent to participate
Adequate knowledge of German	

225 Note: PCC = post-COVID-19 condition

226

227 Until June 2024, only patients attending the PCC clinic at UHB were recruited. Due to 228 recruitment difficulties, recruitment was expanded from July 2024 to include patients from other specialized consultation services or clinics in the broader Basel area with physician-based 229 230 diagnosis. From September 2024 onward, individuals with PCC symptoms and subjective attribution of their persistent symptoms to PCC have been recruited as well. The study is 231 232 advertised in other specialized and outpatient clinics, general practitioners' offices, on public transportation, at conferences and symposia, mailing lists, and via social and other digital 233 234 media. All potential participants are screened for inclusion and exclusion criteria. The study investigator (or their nominee) obtains written informed consent from all study participants. 235 236 Study information is presented by phone or video call if travel for the sole purpose of face-toface recruitment is not possible. As part of the recruitment and informed consent process, the 237 238 investigators (or their designees) explain to each participant the nature of the study, its purpose, the procedures involved, the expected duration, the potential risks and benefits, and 239 240 any inconvenience that may be involved. Each participant is informed that participation in the study is voluntary, that they may withdraw from the study at any time, and that withdrawal of 241 consent will not affect their subsequent medical care. No formal sample size calculation and 242 243 or power analysis has been performed prior to recruitment. The target sample size is 120 participants for the funded period. The rationale for no prior sample size calculation is based 244 on the exploratory nature of the study. The target sample size is based on heuristics and 245

perpetuity. It is made available under a CC-BY-NC 4.0 International license .

246 estimates by the study team regarding of the number of people that sought help at the PCC 247 clinic in 2021 and 2022.

248

249 Horizon Europe Long COVID consortium

The BALCoS study is part of the Horizon Europe Long COVID project. The consortium takes 250 251 a biopsychosocial perspective on PCC and aims to gain a more comprehensive understanding 252 of PCC to identify mechanisms, processes, and biomarkers of the condition, and to develop 253 management strategies and treatment approaches. The research efforts include cohort 254 studies, biomechanistic studies, and (digital) intervention studies. BALCoS is one of the cohort 255 studies being conducted. Participants in the BALCoS cohort are asked to provide blood samples for the consortium's biomechanistic studies. 256

257

Blood samples and assessments¹ 258

259 **Blood Samples**

260 At BL, participants provide blood samples for on-site analysis and for analysis by the 261 consortium (see Table 3). These samples will be analyzed for genomic and human leukocyte antigen (HLA) typing (plasma), COVID-19 antibody profiling (serum), lipidome (serum), 262 263 autoantibody epitopes (serum), and coagulation analyses (citrated plasma). Due to limited resources, for some parameters only a sub-sample of enrolled participants will be sent and 264 analyzed. Participants may refuse genomic analyses and still be included in the study. 265

266

Table 3. Overview of blood sample collection. 267

Blood samples for on-site analysis	Blood samples for the consortium					
RNA tubes for genetic analyses (optional)	EDTA plasma (for genetic analyses; optional)					
EDTA plasma	Citrated plasma					
Serum	Serum					

268 Note: RNA = Ribonucleic Acid, EDTA = Ethylenediaminetetraacetic Acid.

269

270 Neurocognitive Testing

271 CNS Vital Signs (CNSVS, 22) is a computerized neurocognitive test battery that was developed as a routine clinical screening instrument. It consists of seven scientifically valid and 272 reliable neuropsychological tests. The tests are verbal and visual memory, finger tapping, 273 274 symbol digit coding, the Stroop Test, a test of shifting attention, and the continuous 275 performance test. Completion of the tests takes 40-50 minutes. The psychometric properties 276 of the CNSVS tests have been shown to be comparable to the interview-based conventional 277 neuropsychological tests from which they were derived (23).

278

279 **Psychometric Questionnaires**

Visual Analogue Scales (VAS, 24) – Participants answer 4 questions on a VAS with a 10-point 280 Likert scale rating slider ranging from 1 to 10. The guestions cover symptom intensity ("How 281 282 do you currently rate the intensity of your symptoms?", 10 = it can't be worse), functional impairment ("How do you currently rate the impairment caused by your symptoms in everyday 283 284 life?", 10 = it can't be worse), quality of life ("How would you rate your current quality of life?", 285 10 = it can't be better), and work capacity (10 = full work capacity). For work capacity, 286 participants indicate their current work capacity ("current workload in % per week") and their maximum work capacity before the onset of PCC symptoms on a scale from 0% - 100% 287 288 ("Regular workload before symptoms started in % per week").

Functional Capacity – World Health Organization Disability Assessment Schedule (WHODAS 289 290 2.0): The WHODAS 2.0 assesses and classifies disability due to health problems during the 4 previous weeks. The 12-item version is used in this study (25). An example item would be "In 291 292 the past 4 weeks, how much difficulty have you had walking a long distance such as one

¹ All study materials including (computerized) measurements are in German only.

kilometer (or equivalent)?". Items are answered on a 5-point Likert scale ranging from 0 = "none" to 4 = "extreme or impossible".

295 *Quality of Life* – EuroHIS Quality-of-Life-8 (QOL-8, 26): This 8-item instrument assesses 296 quality of life and perceived health during the 4 previous weeks, e.g. by asking "Do you have 297 enough energy to cope with everyday life?". Items are answered on a 5-point Likert scale, with 298 wording varying between questions (e.g., from "very dissatisfied" to "very satisfied").

Somatic Symptom Severity – Patient Health Questionnaire (PHQ-15, 27): The PHQ-15 assesses the severity of somatic symptom over the previous 4 weeks. Participants are asked how much they felt affected by their symptoms, (e.g., back pain). Items are answered on a 3point Likert scale ranging from 0 = "not bothered at all" to 2 = "bothered a lot".

303 *Somatic Distress:* Somatic Symptom Disorder–B Criteria Scale (SSD-12, 28):The SSD-12 304 assesses psychological features of somatic disorders with four questions each on the cognitive 305 (disproportionate and persistent thoughts about the seriousness of one's symptoms), affective 306 (health anxiety), and behavioral (excessive time and energy devoted to these symptoms or 307 health concerns) dimensions. Items are answered on a 5-point Likert scale ranging from 0 = 308 "never" to 4 = "very often".

309 *Depression* – Patient Health Questionnaire Depression Scale (PHQ-8, 29): The PHQ-8 310 assesses the severity of depressive symptoms according to the 4th Edition of the Diagnostic 311 and Statistical Manual of Mental Disorders (DSM-IV;30). Participants are asked whether they 312 have been bothered by symptoms typical for depression (e.g., by having little interest or 313 pleasure in doing things) in the past few weeks. Items are answered on a 4-point Likert scale 314 ranging from 0 = "not at all" to 3 = "almost every day".

Anxiety – Generalized Anxiety Disorder Questionnaire (GAD-7, 31): The GAD-7 measures anxiety. It assesses whether the participant has been bothered by complaints related to anxiety in the past 2 weeks (e.g., by asking about difficulties in relaxing). Items are answered on a 4point Likert scale ranging from 0 = "not at all" to 3 = "almost every day".

Resilience – 11-item Resilience Scale (RS-11, 32): The RS-11 asks about general resilience to life events, e.g. "I feel that I can handle many things at the same time.". Items are answered on a 7-point Likert scale ranging from 1 = "strongly agree" to 7 = "strongly disagree".

Insomnia – Insomnia Severity Index (ISI, 33): The ISI assesses sleep problems. Items are answered on a 5-point Likert scale regarding severity over the past 2 weeks, with wording varying between questions (e.g., from 0 = "very dissatisfied" to 4 = "very satisfied").

Fatigue – 11-item Chalder Fatigue Scale (CFS, 34): The CFS assesses fatigue on a mental
subscale (e.g., by asking "Do you have difficulty concentrating?" and a physical subscale (e.g.,
by asking "Do you need to rest more?"). Items are answered on a 4-point Likert scale ranging
from 0 = "better than usual" to 3 = "much worse than usual".

Stress – Perceived Stress Scale (PSS-10, 35): The PSS assesses the experience of psychological stress in the last 4 weeks. It consists of 10 items, e.g., "In the last month, how often have you been upset about something that happened unexpectedly?". Items are answered on a 5-point Likert scale ranging from 1 = "never" to 5 = "very often".

EMA Questions – After each data collection point (BL, T1, T2, T3), participants answer 8 daily EMA questions for 10 consecutive days. Questions 1-5 are based on the Screening Tool for Psychological Distress (STOP-D, 36), question 6 is based on the EQ-5D (37, 38), question 7 is based on the Single Item Mindfulness Scale (SIMS; 39), and question 8 is based on the Single Item Self Compassion Scale (SISC; 40). The questions are completed in the Research Electronic Data Capture (REDCap, 41) on a 10-point Likert scale ranging from 0 = "not at all" to 9 = "severely". Namely, these questions are: "*In* the last 24h, how much have you been...

- 1) ...bothered by feeling sad, down, or uninterested in life?
- 341 2) ...bothered by feeling anxious or nervous?
- 342 3) ...bothered by feeling stressed?
- 343 4) ...bothered by feeling angry?
- 5) ...bothered by not having the social support you feel you need?
 - 6) ...bothered by difficulties in carrying out your daily activities?
- 346 7) ...fully in the moment, accepting it as it is?
- 347 8) ...high levels of self-compassion for yourself?"
- 348

345

perpetuity. It is made available under a CC-BY-NC 4.0 International license .

349 Measures of physical performance

350 *Grip strength* – Jamar dynamometer (42): Sitting in a chair, the participant is instructed to 351 squeeze the hydraulic grip strength measuring device with one hand, while the other arm rests 352 in their lap. The test is repeated three times for each hand, first for the dominant hand, then 353 for the non-dominant hand. The best value (in kg) for each hand is recorded. Injuries to one or 354 both hands are also recorded.

Functional exercise capacity – 6-minute walking test (43): The distance (total meters), that a participant can walk in six minutes is measured. Pulse and oxygen saturation are assessed at baseline, immediately after finishing the test, and 2 minutes after finishing the test, using a pulse oximeter. Pre- and post-exercise comfort is rated on a 5-point Likert scale ranging from 1 = "very poor" to 5 = "very good". After the test, perceived respiratory and leg exertion is assessed using the Borg Category-Ratio (CR) 10 Scale ranging from 0 = "no exertion" to 10 = "maximum exertion" (44).

362 *Muscular endurance* – Sit-to-Stand Test (STS-60, 45): The STS-60 assesses the number of 363 sit-to-stand cycles that the participant can complete in 60 seconds without using their hands 364 for support. Oxygen saturation at the end of the test is assessed using a pulse oximeter.

365

366 Data collection and management

Data are mainly collected through electronic means: Psychometric questionnaires, EMAs and 367 neurocognitive assessments in the form of online surveys or computerized assessments. Data 368 collection for physical performance measures is paper based. Electronic data capture is done 369 within the REDCap electronic case report form (eCRF). Paper-based data will be entered into 370 371 REDCap by trained members of the study team. Clinical data will be retrieved from the patient's medical records and merged into REDCap or collected in a clinical entry interview with external 372 patients conducted by the study team and then entered into REDCap. Data quality is supported 373 374 by continuous monitoring, plausibility checks of the collected data and checks for missing 375 values by data managers. In addition, participants receive automated reminders from REDCap to complete the questionnaires at T1 and T2, three and seven days after the initial invitation. If 376 377 the questionnaires remain incomplete, the study team contacts participants by phone two 378 weeks after the initial invitation. The study team also monitors adherence to the EMA questions 379 manually and contacts participants by phone if two consecutive days remain incomplete. Data management and monitoring is performed by authorized and experienced study investigators 380 and project employees. In accordance with local laws and regulations, health-related data and 381 382 biological materials are stored for ten years after the publication of the research project. Only authorized personnel have direct access to participant-level data and all electronic documents 383 are stored on UHB-maintained and regularly backed-up server. As soon as possible after data 384 collection all study-related documents are encoded, and participants are only identified by their 385 386 unique participant number. Personal data (i.e., phone numbers and e-mail addresses) will be 387 recorded in REDCap for the purpose of sending out the psychometric questionnaires and EMAs at T1 and T2. Any study-related or participants' personal data are only accessible for 388 389 authorized personnel (e.g., paper-based documentations are locked away in a research office). 390 Members of the study team conducting any research activity (e.g., data monitoring or using a specific software) have been trained by senior members of the team and/or have completed a 391 training course and are acting on Standard Operating Procedures (SOPs) set by UHB or 392 393 developed by the team according to Good Clinical Practice (GCP).

394

395 **Potential Biases**

The inclusion of external participants requires a subjective attribution of persistent symptoms 396 to PCC or a confirmed PCC diagnosis. The diagnostic process of these instances may differ 397 from the diagnostic process of the specialized clinic in the UHB, potentially introducing more 398 heterogeneity into the sample. To address this potentially confounding variable, we will conduct 399 independent t-tests to investigate whether the three groups (subjective attribution, medical 400 401 diagnosis made outside or from the physicians from the UHB) differ in terms of sociodemographic and diagnostic parameters. Since participation in the study is voluntary, 402 403 patients with high motivation, prosocial behavior, or mild or moderate PCC severity may

perpetuity. It is made available under a CC-BY-NC 4.0 International license .

introduce a self-selection bias into the sample, as patients with more severe PCC may not
 have the resources or energy to participate in the study, thereby potentially compromising the
 generalizability of the results.

407

408 Statistical Analysis

409 Data will be analyzed in RStudio (46). Categorical data (e.g., sex) will be reported as counts 410 and percentages. Metric data (e.g., age) will be reported as means with standard deviations. Primary analyses of longitudinal data include the calculation of generalized linear mixed 411 models (GLMMs) for psychometric, neurocognitive, and physical assessment data, and the 412 413 calculation of generalized additive mixed models (GAMMs) for EMAs. In both cases, participants are included as a random effect and time as a fixed effect. A priori subgroups of 414 interest regarding interactions or effect modifying factors are sex, age, and duration of PCC 415 symptoms at BL. Additional covariates will be considered if suspected of confounding 416 influence. Secondary analyses include correlation analyses between EMAs and psychometric 417 418 questionnaires.

419 Missing data will be addressed using appropriate statistical methods, such as multiple imputation, and is categorized into three groups: drop-out, lost-to-follow-up, and 420 421 discontinuation. Drop-out is defined as clear, participant-initiated, written, or verbal withdrawal 422 of consent before they complete the last data collection point (T3), in which case recorded participant data is deleted upon request. Participants opting to drop out of the study cannot 423 424 reenter at a later point. Participants are discontinued from the study if they are not reachable and/or refrain from communicating with the study team before any data collection. In case any 425 426 data was collected (e.g., blood samples from BL), they are declared lost-to-follow-up. Missing 427 data from discontinued participants will not be imputed. Participants are contacted at least four 428 times before they are informed that the study team is no longer trying to contact them to 429 schedule study-related appointments or remind them of adhering to study procedures. 430 Participants are firstly contacted by phone (with a message on the answering machine if the 431 call is not answered), secondly by mail, thirdly via phone again, and then, lastly, by an email explaining that there will be no further contacting attempts. Depending on whether any data 432 433 were collected, the participants are then either declared lost-to-follow-up or discontinued from 434 the study.

436 ETHICS AND DISSEMINATION

437 The study has been approved by the Department of Clinical Research at University Hospital Basel (ID: th22schaefert), the Ethics Commission of Northwest and Central Switzerland (ID: 438 439 2023-00359) and is registered at ClinicalTrial.gov (ID: NCT05781893). The first amendment to this study protocol was submitted to the local ethics committee March 18, 2024, and accepted 440 441 March 22, 2024. The second amendment was submitted on June 3, 2024, and accepted June 442 18, 2024. Further amendments will be submitted to the appropriate bodies if needed. Key 443 results from this study will be published in peer-reviewed journals. The full protocol is 444 accessible through this manuscript. Study results are planned to be presented at conferences, 445 symposia, lectures, and presentations to the scientific community and the public. 446 Dissemination of results is additionally aligned within the consortium to optimize impact. 447 Authorship eligibility of this publication is based on the International Committee of Medical 448 Journal Editors (ICMJE) guidelines (47).

449

435

450 **Risks and Harm to Participants**

There is no additional effort except for additional blood samples and detailed data collection, 451 452 which requires cognitive and temporal efforts for the participants. Participants receive 50 Swiss 453 Francs as compensation for taking part in the study after completing T3, with a proportional 454 amount being paid out in case of withdrawal from the study. No intervention besides standard care including individual remedies is given, no radiation is used, and no vulnerable group is 455 456 recruited. According to Human Research Ordinance (HRO) Art. 7 the risk category of this study 457 is "A". Adverse events and serious adverse events are reported according to HRO Art. 21 and 458 the appropriate bodies to be notified of safety and protective measures according to the Human 459 Research Act (HRA) Art. 15 and HRO Art. 20.

perpetuity. It is made available under a CC-BY-NC 4.0 International license .

460

461 **Public and Patient Involvement**

The measurements and data collection instruments were chosen to adequately reflect the range of PCC symptoms as presented by patients across the globe and informed by the newest published research at the time of study development. The experiences and feedback from patients treated in the PCC clinic at the UHB to date were taken into account when developing and planning the study.

467

468 Artificial Intelligence

469 One author used Grammarly (48) for spell-checking this manuscript and two authors used 470 DeepL (49) to help translate study materials to English.

471

472 Guidelines

We used the Standardized Protocol Items Recommendations for Observational Studies (SPIROS, 50) in the preparation of this protocol, and we will use the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE, 51) guidelines when reporting the results of the study.

477

478 **Open Science**

There are currently no plans to grant public access to participant level data of this study. Participant level data and pooled study data will be made available for consortium partners as part of a joint controllership agreement. A copy of the informed consent form is available upon request. The statistical codes will be made available upon request after analyses are concluded.

483 484

485 Acknowledgements

The authors acknowledge the dedicated engagement and support of Julia Menges, Tabea Rocco, Nadine Celine Grimm, Michèle Häner, and Lukas Ebner. Their feedback on the study materials, inputs for planning and help in achieving core tasks in the study has been an invaluable contribution. Further, the authors acknowledge the support of the master students Aigerim Abdrakhim, Saskia Erni, Stefanie Meier, and Janik Hendry in the ongoing recruitment of participants and their overall contribution to the study. The authors would like to extend their gratitude to the doctors and general staff of the specialized PCC clinic for their efforts and

- 493 contributions towards the success of the study.
- 494

495 **Author Contribution Statement**

- 496 Contributions to this publication are structured according to the Contributor Roles Taxonomy
- 497 (CRediT;52). All authors have contributed, read, and approved the final version of the 498 manuscript.
- 498 Manuscript.
- 499 Conceptualization: SR, ReS, GM, RaS, MM, KB, AM
- 500 Methodology: SR, ReS, GM, RaS, MM, KB, AM
- 501 Software: SR, ReS
- 502 Resources: SR, ReS, GM, RaS, MM, KB, AM
- 503 Writing Original Draft: SR
- 504 Writing Review and Editing: SR, ReS, GM, RaS, MM, KB, AM
- 505 Supervision: GM, RaS
- 506 Project administration: SR, ReS
- 507 Funding acquisition: GM, RaS, MM, KB, AM

perpetuity. It is made available under a CC-BY-NC 4.0 International license .

508 **REFERENCES**

- Coronavirus disease (COVID-19): Post COVID-19 condition [Internet]. 2021. Available
 from: <u>https://www.who.int/news-room/questions-and-answers/item/coronavirus-disease-</u>
 (covid-19)-post-covid-19-condition.
- Nittas V, Puhan M, Gao M, West E. Long COVID: Evolving Definitions, Burden of
 Disease and Socio-Economic Consequences. Swiss School of Public Health. 2021.
- 514 3. Rochmawati E, Iskandar, A.C., & Kamilah, F. . Persistent symptoms among post-COVID-515 19 survivors: A systematic review and meta-analysis. J Clin Nurs. 2024 Jan;33(1).
- Nittas V, Gao M, West EA, Ballouz T, Menges D, Wulf Hanson S, et al. Long COVID
 Through a Public Health Lens: An Umbrella Review. Public Health Rev. 2022;43.
- 517 Thirdight a Fublic Treatil Lens. An Onbrena Review. Fublic Treatil Rev. 2022,43.
 518 5. de Bruijn S, van Hoek AJ, Mutubuki EN, Knoop H, Slootweg J, Tulen AD, et al. Lower
 519 prevalence of post-Covid-19 Condition following Omicron SARS-CoV-2 infection.
 520 Heliyon. 03/30/2024;10(7).
- 521 6. Lippi G, Sanchis-Gomar F, Henry BM. COVID-19 and its long-term sequelae: what do 522 we know in 2023? Polish archives of internal medicine. 04/19/2023;133(4).
- Nehme M, Vetter P, Chappuis F, Kaiser L, Guessous I, Nehme M, et al. Prevalence of
 Post-Coronavirus Disease Condition 12 Weeks After Omicron Infection Compared With
 Negative Controls and Association With Vaccination Status. Clin Infect Dis.
 2023;76(9):1567-75.
- Perlis RH, Santilla M, Ognyanova K, Safarpour A, Lunz Trujillo K, Simonson MD, et al.
 Prevalence and Correlates of Long COVID Symptoms Among US Adults. JAMA network
 open. 10/03/2022;5(10).
- Tene L, Bergroth T, Eisenberg A, Shapiro Ben David S, Chodick G. Risk factors, health outcomes, healthcare services utilization, and direct medical costs of patients with long COVID. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases. 2023 Mar;128.
- Subramanian A, Nirantharakumar K, Hughes S, Myles P, Williams T, Gokhale KM, et al.
 Symptoms and risk factors for long COVID in non-hospitalized adults. Nat Med.
 2022;28(8):1706-14.
- 537 11. Desai AD, Lavelle M, Boursiquot BC, Wan EY. Long-term complications of COVID-19.
 538 American journal of physiology Cell physiology. 01/01/2022;322(1).
- 539 12. Davis HE, McCorkell L, Vogel JM, Topol EJ. Long COVID: major findings, mechanisms
 540 and recommendations. Nature Reviews Microbiology. 2023;21(3):133-46.
- 13. Choutka J, Jansari V, Hornig M, Iwasaki A. Unexplained post-acute infection syndromes.
 Nat Med. 2022;28(5):911-23.
- Merad M, Blish CA, Sallusto F, Iwasaki A. The immunology and immunopathology of
 COVID-19. Science. 2022;375(6585):1122-7.
- Pretorius E, Vlok M, Venter C, Bezuidenhout JA, Laubscher GJ, Steenkamp J, et al.
 Persistent clotting protein pathology in Long COVID/Post-Acute Sequelae of COVID-19
 (PASC) is accompanied by increased levels of antiplasmin. Cardiovasc Diabetol.
 2021;20(1).
- 549 16. Dani M, Dirksen A, Taraborrelli P, Torocastro M, Panagopoulos D, Sutton R, et al.
 550 Autonomic dysfunction in 'long COVID': rationale, physiology and management 551 strategies. Clin Med (Northfield II). 2021;21(1):e63-e7.
- 552 17. Engelmann P, Reinke M, Stein C, Salzmann S, Löwe B, Toussaint A, et al. Psychological
 553 factors associated with Long COVID: a systematic review and meta-analysis.
 554 eClinicalMedicine. 2024;74:102756.
- Allwang C, Frank T, Bruckmann P, Dinkel A, Binneboese M, Wallis H, et al. Addressing
 psychosocial needs in patients with Long-COVID (PsyLoCo-Study): study protocol of a
 pilot-study of a specialized modular intervention. Frontiers in Psychiatry. 2024;15.
- 19. Loft MI, Foged EM, Koreska M. An Unexpected Journey: The Lived Experiences of
 Patients with Long-Term Cognitive Sequelae After Recovering from COVID-19. Qual
 Health Res. 2022;32(8-9):1356-69.
- 20. Crook H, Raza S, Nowell J, Young M, Edison P. Long covid—mechanisms, risk factors,
 and management. BMJ. 2021;374:n1648.

21. Parotto M, Gyöngyösi M, Howe K, Myatra SN, Ranzani O, Shakar-Hari M, et al. Post-563 564 acute sequelae of COVID-19: understanding and addressing the burden of multisystem manifestations. The Lancet Respiratory medicine. 2023 Aug;11(8). 565 22. CNS Vital Signs. https://www.cnsvs.com/index.html: CNS Vital Signs LLC. 566 23. Gualtieri CT, Johnson LG. Reliability and validity of a computerized neurocognitive test 567 568 battery, CNS Vital Signs. Arch Clin Neuropsychol. 2006;21(7):623-43. 569 24. Crichton N. Visual analogue scale (VAS). J Clin Nurs. 2001;10(5):706-6. 570 25. Üstün TB, Kostanjsek N, Chatterji S, Rehm J. Measuring health and disability: Manual 571 for WHO disability assessment schedule WHODAS 2.0: World Health Organization; 572 2010. 26. Schmidt S, Mühlan H, Power M. The EUROHIS-QOL 8-item index: psychometric results 573 of a cross-cultural field study. Eur J Public Health. 2005;16(4):420-8. 574 575 27. Kroenke K, Spitzer RL, Williams JBW. The PHQ-15: Validity of a New Measure for 576 Evaluating the Severity of Somatic Symptoms. Psychosom Med. 2002;64(2):258-66. 577 28. Toussaint A, Murray AM, Voigt K, Herzog A, Gierk B, Kroenke K, et al. Development and 578 Validation of the Somatic Symptom Disorder–B Criteria Scale (SSD-12). Psychosom 579 Med. 2016;78(1):5-12. 580 29. Kroenke K, Strine TW, Spitzer RL, Williams JBW, Berry JT, Mokdad AH. The PHQ-8 as a measure of current depression in the general population. J Affect Disord. 581 582 2009;114(1):163-73. 583 30. Diagnostic and statistical manual of mental disorders: American Psychiatric Association; 2000. 584 585 31. Williams N. The GAD-7 questionnaire. Occup Med. 2014;64(3):224-. 32. Kocalevent R-D, Zenger M, Heinen I, Dwinger S, Decker O, Brähler E. Resilience in the 586 General Population: Standardization of the Resilience Scale (RS-11). PLoS One. 587 588 2015;10(11):e0140322. 589 33. Morin CM. Insomnia severity index. 1993. 34. Jackson C. The Chalder Fatigue Scale (CFQ 11). Occup Med. 2014;65(1):86-. 590 591 35. Cohen S, Kamarck T, Mermelstein R. A global measure of perceived stress. J Health Soc 592 Behav. 1983;24(4):385-96. 593 36. Young Q-R, Ignaszewski A, Fofonoff D, Kaan A. Brief Screen to Identify 5 of the Most 594 Common Forms of Psychosocial Distress in Cardiac Patients: Validation of the 595 Screening Tool for Psychological Distress. J Cardiovasc Nurs. November-December 596 2007;22(6). 37. Ludwig K, Graf von der Schulenburg JM, Greiner W. German Value Set for the EQ-5D-597 598 5L. Pharmacoeconomics. 2018 Jun;36(6). 38. Herman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D, et al. Development and 599 600 preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Quality of life 601 research : an international journal of quality of life aspects of treatment, care and 602 rehabilitation. 2011 Dec;20(10). 603 39. Meier BP, Konrath S, Fetterman AK, Dillard AJ, James C, Weinstein E, et al. 604 Development and Validation of the Single-Item Mindfulness Scale (SIMS). J Pers 605 Assess. 2022;105(6). 40. Zhang JW, Howell RT, Chen S, Goold AR, Bilgin B, Chai WJ, et al. 'I have high self-606 607 compassion': A face-valid single-item self-compassion scale for resource-limited 608 research contexts. Clin Psychol Psychother. 2022 Jul;29(4). 41. Research Electronic Data Capture (REDCAp). https://www.project-redcap.org/: 609 Vanderbilt University. 610 42. American Society for Surgery of the Hand. The Hand: Examination and Diagnosis. 2nd 611 612 ed: Churchill Livingstone, Edinburgh; 1983. 43. Butland RJ, Pang J, Gross ER, Woodcock AA, Geddes DM. Two-, six-, and 12-minute 613 walking tests in respiratory disease. Br Med J (Clin Res Ed). 1982;284(6329):1607-8. 614 615 44. Borg G. Borg's perceived exertion and pain scales. Champaign, IL, US: Human Kinetics; 616 1998. viii, 104-viii, p.

- 617 45. Koufaki P, Mercer TH, Naish PF. Effects of exercise training on aerobic and functional 618 capacity of end-stage renal disease patients. Clin Physiol Funct Imaging. 2002;22(2):115-24. 619
- 46. Racine JS. RSTUDIO: A PLATFORM-INDEPENDENT IDE FOR R AND SWEAVE. 620 Journal of Applied Econometrics. 2012;27(1):167-72. 621
- 47. Editors ICoMJ. Recommendations for the Conduct, Reporting, Editing, and Publication 622 of Scholarly worrk in Medical Journals https://www.icmje.org/recommendations/2024 623 624 [updated 2024.
- 48. Grammarly AI writing assistance https://www.grammarly.com/: Grammarly Inc.; 2009 625 626 [Available from: https://www.grammarly.com/.
- 49. DeepL AI-assisted translations https://www.deepl.com/de/translator: DeepL SE; 2017 627 [Available from: https://www.deepl.com/de/translator. 628
- 50. Mahajan R, Burza S, Bouter LM, Sijtsma K, Knottnerus A, Kleijnen J, et al. Standardized 629 630 Protocol Items Recommendations for Observational Studies (SPIROS) for Observational Study Protocol Reporting Guidelines: Protocol for a Delphi Study. JMIR Res Protoc. 631 2020;9(10):e17864. 632
- 51. von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP, et al. 633 634 The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet (London, England). 635 10/20/2007;370(9596). 636
- 52. Credit Author Statement [Policy]. https://www.elsevier.com/researcher/author/policies-637
- and-guidelines/credit-author-statement: Elsevier; [Available from: 638 https://www.elsevier.com/researcher/author/policies-and-guidelines/credit-author-639 640 statement.

641